GLP-1 receptor agonists in NAFLD.

Fiche publication


Date publication

avril 2017

Journal

Diabetes & metabolism

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PETIT Jean-Michel, Pr VERGES Bruno


Tous les auteurs :
Petit JM, Vergès B

Résumé

Non-alcoholic fatty liver disease (NAFLD) is very common in patients with type 2 diabetes (T2D), with approximately two-thirds having a diagnosis of the disease. Currently, the only validated treatment for NAFLD is weight loss. A number of studies of animal models and human trials have evaluated the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on liver fat content and suggest that the treatment could represent a new alternative for NAFLD management. In this review, our focus is on the main studies regarding the effects of GLP-1RAs on NAFLD. Also, the mechanisms that might explain their beneficial effects on liver diseases are analyzed.

Mots clés

Fibrosis, GLP-1 receptor agonists, Non-alcoholic fatty liver disease, Steatosis, type 2 diabetes

Référence

Diabetes Metab.. 2017 Apr;43 Suppl 1:2S28-2S33